Lawrence Eichenfield
As seen in:
Wiley Online Library,
JAMA (The Journal of the American Medical Association),
HCP Live,
Dialnet - Universidad de La Rioja,
American Journal of Managed Care,
Journal of The American Academy of Dermatology (JAAD),
Dermatology Times,
Contemporary Pediatrics,
Managed Healthcare Executive,
Practical Dermatology
and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Lawrence Eichenfield
What Phase 2 Nemolizumab Data Show in Children 2-11 With Atopic Dermatitis
Nemolizumab (Nemluvio) produced durable improvements in itch, sleep disturbance and quality of life among children aged 2 - 11 years with moderate-to-severe atopic dermatitis in a phase 2 open-label study, according to data Galderma presented at the 2026 Pediatric Dermatology Research Alliance (PeDRA) Annual Conference.¹ Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children’s Hospital-San Diego, professor of dermatology and pediatrics and vice chair of the...
Q&A: First Pediatric Eczema Guidelines and New Topical Options Down to Age 2
The American Academy of Dermatology (AAD) issued its first pediatric-specific atopic dermatitis guidelines in 2026, covering primary prevention and comorbidity awareness for children with the disease.¹ The prevention guideline gives moisturizers a conditional recommendation to reduce eczema occurrence in children aged 6 months to 3 years, while water softeners and dust mite avoidance showed no preventive benefit.¹ Eosinophilic esophagitis carries the only high-certainty comorbidity link to...
New Nonsteroidal Options Expand for Pediatric Atopic Dermatitis
In a new discussion with HCPLive, Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego and professor of dermatology and pediatrics at the University of California, San Diego, touched on recent approvals and emerging data in the atopic dermatitis.1,2 In his interview with HCPLive, treatments for pediatric atopic dermatitis were highlighted alongside new insights in the field, continuing Eichenfield’s discussion of his 2026 Maui Derm...
Q&A: Where the Pediatric Atopic Dermatitis Systemic Pipeline Stands
Systemic treatment options for pediatric atopic dermatitis are expanding rapidly below age 12, where dupilumab has long stood as the only biologic approved in most of the world.
Recent AAD Guidelines Address Pediatric Atopic Dermatitis Prevention
Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego and professor of dermatology and pediatrics at the University of California, San Diego, discussed key takeaways from his 2026 Maui Derm conference session, ‘Atopic Dermatitis and Itch Update 2026.’1,2 In his session, he highlighted the American Academy of Dermatology (AAD)'s first pediatric-specific atopic dermatitis guidelines and what they mean for clinical practice.
What the ADorable-1 Trial Means for Pediatric Eczema Care
In newly-released phase 3 findings, lebrikizumab therapy produced meaningful improvements in itch, quality of life, and overall disease burden among children and adolescents with moderate-to-severe atopic dermatitis. These efficacy and safety findings were released from the ADorable-1 trial and presented at the Society of Pediatric Dermatology conference.
ADorable-1 Results: Key Findings in Pediatric Atopic Dermatitis
The growing armamentarium of treatments for pediatric atopic dermatitis continues to generate new data available for clinicians managing moderate-to-severe cases of this skin disease.
Tolerability of Roflumilast Cream 0.05% in Children with Eczema, With Lawrence Eichenfield, MD
Lawrence F. Eichenfield, MD, of Rady Children’s Hospital, spoke in another segment of his HCPLive interview on recent long-term safety and tolerability data drawn from the INTEGUMENT-OLE study, reflecting on what roflumilast cream .05% (Zoryve) could be for toddlers and preschoolers with atopic dermatitis.1,2 These findings were poster data presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting.
New Data Support Roflumilast Cream in Infants with Eczema Over 4 Weeks, With Lawrence Eichenfield, MD
Roflumilast cream .05% (Zoryve) has demonstrated meaningful efficacy and a favorable safety profile among infants with mild to moderate atopic dermatitis as young as 3 months, according to new data.1 These phase 2 data were presented during a late-breaking podium session at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, adding new information to the growing body of evidence behind roflumilast cream for infants aged 3 months to less than 24 months with mild to...
Long-Term Safety of Roflumilast Cream for Children, With Lawrence Eichenfield, MD
New long-term INTEGUMENT-OLE open-label extension trial data reinforce roflumilast cream .05% (ZORYVE) as a durable, well-tolerated non-steroidal medication for children aged 2 - 5 years living with atopic dermatitis, with efficacy continuing to build over the full 56-week study period.1,2 In the second half of his discussion with the team at HCPLive, Eichenfield, chief of pediatric and adolescent dermatology at Rady Children's Hospital–San Diego, highlighted what those new results could mean...
On New Roflumilast Cream Data for Atopic Dermatitis in Children, With Lawrence Eichenfield, MD
In a new HCPLive interview, Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital–San Diego and lead author of the INTEGUMENT-OLE publication, highlighted the value of new long-term data supporting roflumilast cream .05% (ZORYVE) as a sustained treatment option for young children living with atopic dermatitis.1,2 Eichenfield opened by contextualizing the need for the open-label extension study.
Long‐Term Safety and Efficacy of Once‐Daily and Proactive Twice‐Weekly Roflumilast Cream 0.05% for Mild‐to‐Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52‐Week, Phase 3 Trial (INTEGUMENT‐OLE) - Eichenfield - Pediatric Dermatology - Wiley O
1 Introduction Global prevalence of atopic dermatitis (AD) in those aged 6 months to < 18 years is 12%–15% [1]. Itch, sleep deprivation, impaired social functioning, and mental/physical comorbidities occurring with AD signs/symptoms [2] can negatively impact patient and family quality of life [2, 3].
Highlighting Therapeutic Updates for Atopic Dermatitis and Itch, With Lawrence Eichenfield, MD
At the 2026 Maui Derm Hawaii conference, the ‘Atopic Dermatitis and Pruritus: Current Concepts and Therapeutics for 2026’ talk was presented, with 3 speakers highlighting the emergence of monoclonal antibodies, oral Janus Kinase (JAK) inhibitors, and topical non-steroidal drugs into dermatology practices.1,2 Lawrence F.
Acne and Rosacea Treatment Updates for 2026, With Lawrence Eichenfield, MD
This interview from the Maui Derm 2026 conference features Lawrence Eichenfield, MD, discussing takeaways from his talk ‘Acne and Rosacea: Update 2026.’ At the 2026 Maui Derm Hawaii conference, a session was presented titled ‘Acne and Rosacea: Update 2026,’ featuring a discussion of challenging case scenarios and new insights into acne and rosacea treatment paradigms.1,2 This session was presented by several speakers, 1 of whom was Lawrence F.
Comparing Roflumilast Cream to Other Topicals for Atopic Dermatitis, With Lawrence Eichenfield, MD
Following the US Food and Drug Administration (FDA) approval of roflumilast (Zoryve) cream 0.05% for atopic dermatitis in patients aged 2 - 5 years, HCPLive interviewed Lawrence Eichenfield, MD, about his team’s data on the new non-steroidal option.1,2 Roflumilast cream’s safety and efficacy as a long-term alternative to topical corticosteroids for children was highlighted in this recent interview by Eichenfield, the chief of pediatric and adolescent dermatology at Rady Children's...
Significance of Roflumilast Approval for Atopic Dermatitis in Children, With Lawrence Eichenfield, MD
Roflumilast cream 0.05% (Zoryve), a non-steroidal topical designed for the treatment of mild to moderate atopic dermatitis in children ages 2 - 5 years, was approved by the US Food and Drug Administration (FDA) on October 6, 2025.1,2 The approval of roflumilast cream 0.05 % followed recent trial data confirming the drug’s safety and efficacy as a long-term alternative to topical corticosteroids for children.
Patient‐Reported Impact of Atopic Dermatitis on Pediatric and Adolescent Patients With Moderate‐To‐Severe Disease: Results of a Real‐World, Cross‐Sectional Survey
1 Introduction Atopic dermatitis (AD) is a chronic, inflammatory, relapsing skin disorder and one of the most common and burdensome diseases in children [1]. In Europe and the United States (US), AD affects up to 20% of children [2-4]. In around 80% of cases, the onset of AD occurs in the first few years of life [5], with 60% experiencing relapses into adolescence [6].
Significance of Icotrokinra Findings for Adolescents with Psoriasis, with Lawrence Eichenfield, MD
A subgroup analysis of the ICONIC-LEADa study had its findings presented at the World Congress of Pediatric Dermatology Annual Meeting, demonstrating that adolescents living with moderate-to-severe psoriasis given once-daily treatment with icotrokinra (JNJ-2113) saw increased rates of clear or almost clear skin at 16 weeks versus placebo.1 After these data were released by Johnson & Johnson, the HCPLive editorial team interviewed Lawrence Eichenfield, MD, chief of pediatric and adolescent...
Notable Attributes of Icotrokinra for Adolescents with Psoriasis, with Lawrence Eichenfield, MD
New data released by Johnson & Johnson from a subgroup analysis of the ICONIC-LEADa study were presented at the 2025 World Congress of Pediatric Dermatology (WCPD) Annual Meeting and demonstrated that adolescents with moderate-to-severe psoriasis treated with once-daily icotrokinra (JNJ-2113) received higher rates of clear or almost clear skin at the 16-week mark versus placebo.1 These new data resulted the first ever phase 3 registrational analysis of moderate-to-severe plaque psoriasis to...
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials
Ayuda Buscar en la ayuda Buscar en la ayuda Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials Autores: Eric L. Simpson, Lawrence F. Eichenfield, Javier Alonso Llamazares, Zoe Diana Draelos, Laura K. Ferris, Seth B. Forman, Melinda J. Gooderham, Mercedes E. Gonzalez, Adelaide A. Hebert, Leon H. Kircik, Mark Lomaga, Angela Moore, Kim A. Papp, Vimal H.
Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis: A Randomized Clinical Trial
Key Points Question Is topical PF-07038124 a safe and effective treatment for atopic dermatitis (AD) and plaque psoriasis? Findings This phase 2a randomized clinical trial of 104 patients, 70 with AD and 34 with plaque psoriasis, found that PF-07038124, 0.01%, administered once daily was more effective than vehicle after 6 weeks of treatment. Treatment with PF-07038124 was generally well tolerated, with no application site reactions.
Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Atopic Dermatitis in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age | SKIN The Journal of Cutaneous Medicine
Main Article Content Keywords atopic dermatitis, eczema, tapinarof cream 1% once daily, efficacy, safety, AhR agonist References 1. Weidinger S, et al. Lancet. 2016;387:1109–1122. 2. Bieber T. N Engl J Med. 2008;358:1483–1494. 3. Carroll CL, et al. Pediatr Dermatol. 2005;22:192–199. 4. Lewis-Jones S. Int J Clin Pract. 2006;60:984–992. 5. Nygaard U, et al. Dermatology. 2017;233:333–343. 6. Wu JJ, et al. J Eur Acad Dermatol Venereol. 2016;30:1115–1119. 7. Menter A, et al. J Am Acad Dermatol. 2011;65:137–174. 8. Goh MS, et al.
The vIGA‐AD scale for atopic dermatitis: Uptake in the past 5 years and position of the International Eczema Council
Please review our Terms and Conditions of Use and check box below to share full-text version of article. I have read and accept the Wiley Online Library Terms and Conditions of Use Use the link below to share a full-text version of this article with your friends and colleagues. Learn more.
Efficacy and Safety of Roflumilast Cream 0.15% in Adults and Children Aged ≥6 Years With Mild to Moderate Atopic Dermatitis in Two Phase 3 Trials (INTEGUMENT-1 and INTEGUMENT-2) | SKIN The Journal of Cutaneous Medicine
Main Article Content Keywords Atopic Dermatitis, roflumilast, phosphodiesterase 4 inhibitor References 1. Gooderham MJ, et al. J Drugs Dermatol. 2023;22:139–147. 2. Berk DR, Osborne DW. Society for Investigative Dermatology Annual Meeting, Portland, OR, USA, 2022. 3. Dong C, et al. J Pharmacol Exp Ther. 2016;358:413–422. 4. Schafer PH, et al. Cell Signal. 2014;26:2016–2029. Article Sidebar Article Details How to Cite Simpson, E., Eichenfield, L., Gooderham, M., Gonzalez, M.
Tralokinumab therapy for moderate‐to‐severe atopic dermatitis: Clinical outcomes with targeted IL‐13 inhibition
Pivotal phase 3 clinical trials of tralokinumab in adult AD The phase 3 clinical trials in adults, ECZTRA 1/2 (monotherapy),22 and ECZTRA 3 (combination with topical corticosteroids [TCS] as needed)21 are summarized in Figure 2 and Table 1. Overview of study design and inclusion criteria for pivotal phase 3 tralokinumab clinical trials: ECZTRA 1, 2, and 3.
Understanding Flares in Pediatric and Adolescent Patients with Moderate or Severe Atopic Dermatitis: A Real-world Study in the United States and Europe | SKIN The Journal of Cutaneous Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License. All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose.
Efficacy and Safety of Triple-Combination Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Polymeric Gel in Pediatric Participants with Acne | SKIN The Journal of Cutaneous Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License. All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose.
Isotretinoin does not contribute to increased neuropsychiatric risk in the overall acne population, but risk management during treatment remains essential
Conflicts of interest: J.R. was a committee member for the NICE guideline ‘Acne management’, 2021. L.E. has served as a scientific adviser, consultant and/or clinical study investigator for Almirall, Cassiopea, Dermata, Galderma and Ortho Dermatologics. Abstract Linked Article: Paljarvi et al. Br J Dermatol 2022; 187:64–72.
Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years with Uncontrolled, Severe Atopic Dermatitis
Main Article Content Michael Cork Sheffield Dermatology Research, University of Sheffield, Sheffield, UK Diamant Thaçi University of Lübeck, Lubeck, Germany Lawrence Eichenfield University of California, San Diego, CA; Rady Children’s Hospital, San Diego, CA Peter Arkwright University of Manchester, Manchester, UK Zhen Chen Regeneron Pharmaceuticals, Inc., Tarrytown, NY Mohamed Kamal Regeneron Pharmaceuticals, Inc., Tarrytown, NY John O'Malley Sanofi, Cambridge, MA Ashish Bansal Regeneron...
Phase IV Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Halobetasol propionate Foam, 0.05% in Adolescent Subjects with Plaque Psoriasis | SKIN The Journal of Cutaneous Medicine
Main Article Content Adelaide Hebert Rhonda Schrieber Debbie Glaab Lawrence Eichenfield Keywords Psoriasis, Plaque Psoriasis, Topical Steroid, Halobetasol, Adrenal Suppression, Adolescent Abstract Abstract not available. References 1. Bronker et al. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Pediatr Drugs (2015) 17:373-384 2. Paller et al. Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis. J Drugs Dermatol.
Isotretinoin and iPledge Program patient information video: A new modality that improves patient comprehension
To the Editor: Evidence confirms the lack of readability and comprehension of the current iPledge Program patient educational materials. Today, because patients obtain much of their information online and through popular websites or social media, it is important to provide them with quality information via these platforms. Unfortunately, there is a diverse range of quality in the currently available online resources.
Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis in Pediatric Patients
Main Article Content Lawrence F Eichenfield Boni Elewski Jeffrey L Sugarman Ted Rosen Aditya Gupta Wendy Cantrell Radhakrishnan Pillai Abby Jacobson Keywords Onychomycosis, Pediatrics, Efinaconazole, Topical, Safety, Pharmacokinetics, Efficacy Abstract Abstract not available. Abstract 1 | Poster PDF Downloads 0 References 1. Gupta AK, et al. Pediatr Dermatol. 2018;35(5):552-559. 2.
Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients: Open-label phase 4 study
To the Editor: Onychomycosis is a chronic fungal nail infection affecting an estimated 0.35% to 5.5% of children worldwide, although parents and health care practitioners are hesitant to use long-term systemic treatments in children. 2 Eichenfield L.F. Friedlander S.F. Pediatric onychomycosis: the emerging role of topical therapy. J Drugs Dermatol.
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis
Background An Investigator Global Assessment (IGA) is recommended by health agencies for drug registration in atopic dermatitis (AD). Current IGA scales lack standardization. Objectives To develop an IGA scale, training module, and clinical certification examination for use in AD trials; establish content validity; and assess reliability. Methods Expert dermatologists participated in the development of the validated IGA for AD (vIGA-ADTM).
Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris
Background Androgens foster acnegenic pathways. Objective To assess the long-term safety of an androgen receptor inhibitor, clascoterone cream, 1%, in patients who participated in phase 3 studies. Methods Clascoterone cream was applied twice daily for up to 9 months to the face or trunk, or both. Treatment-emergent adverse events (TEAEs) and local skin reactions were evaluated at months 1, 3, 6, and 9, and at any unscheduled visit(s).
Label Update: Low Risk of Antibiotic Resistance with Almirall's Seysara
June 18, 2020 The FDA approved a label change stating that P. acnes strains displayed a low propensity for the development of resistance to sarecycline. Personnel/Company News Lawrence Eichenfield, MD, FAAD The FDA approved a label update for Almirall's Seysara stating that P. acnes strains displayed a low propensity for the development of resistance to sarecycline. This information is included in the Microbiology Section (12.4) of the prescribing information.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Lawrence
Contact Lawrence, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack